CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a bench-top instrument for assessing the motility of therapeutic immune cells used in cancer treatment. The goal is to enhance quality control in cell-based therapies, ensuring that only effective immune cells are used for patient treatments.
Cell-based therapy (CBT) for cure of difficult-to-treat cancer types is the most disruptive innovation in personalized medicine.
However, patient-specific production of therapeutic immune cells is expensive and associated with remaining risks.
In particular, it is known that only actively migrating immune cells are efficient against tumours cells, while inactive therapeutic cells can elicit adverse effects.
Yet, there is no quality control (QC) regarding motility of therapeutic cells before pati…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
